Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The presence of tumor-infiltrating lymphocytes in triple-negative breast cancers is correlated with improved outcomes. Ras/MAPK pathway activation is associated with significantly lower levels of tumor-infiltrating lymphocytes in triple-negative breast cancers and while MEK inhibition can promote recruitment of tumor-infiltrating lymphocytes to the tumor, here we show that MEK inhibition adversely affects early onset T-cell effector function. We show that α-4-1BB and α-OX-40 T-cell agonist antibodies can rescue the adverse effects of MEK inhibition on T cells in both mouse and human T cells, which results in augmented anti-tumor effects in vivo. This effect is dependent upon increased downstream p38/JNK pathway activation. Taken together, our data suggest that although Ras/MAPK pathway inhibition can increase tumor immunogenicity, the negative impact on T-cell activity is functionally important. This undesirable impact is effectively prevented by combination with T-cell immune agonist immunotherapies resulting in superior therapeutic efficacy.MEK inhibition in breast cancer is associated with increased tumour infiltrating lymphocytes (TILs), however, MAPK activity is required for T cells function. Here the authors show that TILs activity following MEK inhibition can be enhanced by agonist immunotherapy resulting in synergic therapeutic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“both BRAF and MEK inhibitors (including the FDA-approved agents vemurafenib, dabrafenib, and trametinib) mediate various cancer-cell-dependent immunostimulatory effects”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Dushyanthen et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“improved antigen presentation on MHC class I molecules (Dushyanthen et al., 2017; Kang et al., 2019; Liu et al., 2015)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Dushyanthen et al., 2017
Experimental — accuracy not yet measuredIn the citing paper
“the ability of PD-1 or PD-L1 blockers (Liu et al., 2015; Loi et al., 2016) as well as immunostimulatory antibodies targeting TNF receptor superfamily member 4 (TNFRSF4, best known as OX40) or TNFRSF9 (best known as 4-1BB) (Dushyanthen et al., 2017) to improve the therapeutic activity of MEK inhibition in vivo , in syngeneic immunocompetent settings”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Dushyanthen et al., 2017
In the citing paper
“loss of antigen presentation, TEFF cell exhaustion, and tumor infiltration by immunosuppressive cells have been commonly observed when tumors progress on KRAS, BRAF, or MEK inhibitors, in both preclinical (Dushyanthen et al., 2017; Liu et al., 2017b) and clinical settings (Frederick et al., 2013; Hugo et al., 2015)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Dushyanthen et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C., Philippakis, A. A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,456
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cited by
Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis
Erkes, D. A., Cai, W., Sanchez, I. M., Purwin, T. J., Rogers, C., Field, C. O., Berger, A. C., Hartsough, E. J., Rodeck, U., Alnemri, E. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0672 · Cited by 459
“S3D and S3E), consistent with previous publications suggesting that MEKi inhibits T-cell function (21, 23).”
ResultKato, T., Noma, K., Ohara, T., Kashima, H., Katsura, Y., Sato, H., Komoto, S., Katsube, R., Ninomiya, T., Tazawa, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0205 · Cited by 367
“However, there are many problems that remain to be solved with regard to T-cell–mediated immunotherapies (11, 12).”
BackgroundMechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 272
El Bairi, K., Haynes, H. R., Blackley, E., Fineberg, S., Shear, J., Turner, S., de Freitas, J. R., Sur, D., Amendola, L. C., Gharib, M., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00346-1 · Cited by 268
Self-citationImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Metadata
- Authors
- Dushyanthen, S., Teo, Z. L., Caramia, F., Savas, P., Mintoff, C. P., Virassamy, B., Henderson, M. A., Luen, S. J., Mansour, M., Kershaw, M. H., Trapani, J. A., Neeson, P. J., Salgado, R., McArthur, G. A., Balko, J. M., Beavis, P. A., Darcy, P. K., & Loi, S.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- Institut Jules Bordet (BE)
- Vanderbilt University (US)
- Corresponding author
- Beavis, Paul A.
- Darcy, Phillip K.
- Loi, Sherene
- ORCID
- Venue
- Nature Communications
- Published
- 2017-09-19
- Volume
- 8
- Issue
- 1
- Pages
- 606-606
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5605577
- OpenAlex
- W2754588487
- Cited by
- 124
- References
- 66
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 12 · 2023: 11 · 2022: 19 · 2021: 18 · 2020: 17 · 2019: 14 · 2018: 9 · 2017: 2
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Breast Cancer Research Foundation
- National Breast Cancer Foundation
- Medical Research Council
- National Health and Medical Research Council (1058388, 1041828)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- MEK inhibition, triple-negative breast cancer, tumor-infiltrating lymphocytes, RAS/MAPK pathway, 4-1BB, OX40, T cell effector function, combination immunotherapy, antitumor immunity
- MeSH terms
- Animals, Breast Neoplasms, Female, Humans, Immunotherapy, Pyridones, Pyrimidinones, T-Lymphocytes, Mammary Neoplasms, Animal, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, MAP Kinase Signaling System, Cell Line, Tumor, Protein Kinase Inhibitors, MAP Kinase Kinase 1, MAP Kinase Kinase 2, Cell Proliferation, Mice, OX40 Ligand, 4-1BB Ligand, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. https://app.cochat.ai/papers/10.1038/s41467-017-00728-9
- The paper
- Dushyanthen, S., Teo, Z. L., Caramia, F., Savas, P., Mintoff, C. P., Virassamy, B., Henderson, M. A., Luen, S. J., Mansour, M., Kershaw, M. H., Trapani, J. A., Neeson, P. J., Salgado, R., McArthur, G. A., Balko, J. M., Beavis, P. A., Darcy, P. K., & Loi, S. (2017). Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. Nature Communications. https://doi.org/10.1038/s41467-017-00728-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.